AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: AdventHealth Orlando, Virginia Cancer Specialists, The US Oncology Network, New York University, Hospital Universitario 12 De Octubre, German Center for Lung Research, LungenClinic Grosshansdorf, Shanghai Chest Hospital, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Zhejiang Cancer Hospital, University of Chinese Academy of Sciences
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3171557954